<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Chronic mucocutaneous candidiasis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Chronic mucocutaneous candidiasis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Chronic mucocutaneous candidiasis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Chaim M Roifman, CM, MD, FRCPC, FCACB
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jordan S Orange, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elizabeth TePas, MD, MS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 26, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H571977">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chronic mucocutaneous candidiasis (CMCC) is a heterogeneous group of syndromes with the common features of chronic noninvasive
         <em>
          Candida
         </em>
         infections of the skin, nails, and mucous membranes that are usually resistant to topic treatment and absence of invasive fungal infections. The classic forms have associated autoimmune manifestations (most commonly endocrinopathies), and patients may have other microbial infections. Milder forms have oral candidiasis with or without associated staphylococcal skin infections. CMCC is caused by genetic defects in the immune system  (
         <a class="graphic graphic_figure graphicRef117876" href="/z/d/graphic/117876.html" rel="external">
          figure 1
         </a>
         ).
        </p>
        <p>
         The pathogenesis, clinical manifestations of identified genetic defects, differential diagnosis, and treatment of CMCC are reviewed here. A general discussion of
         <em>
          Candida
         </em>
         infections and their clinical manifestations is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/2416.html" rel="external">
          "Overview of Candida infections"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5972.html" rel="external">
          "Candida infections in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2427.html" rel="external">
          "Esophageal candidiasis in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H564453640">
         <span class="h1">
          CLASSIC FORMS OF CMCC WITH ASSOCIATED AUTOIMMUNITY
         </span>
         <span class="headingEndMark">
          —
         </span>
         CMCC traditionally refers to a heterogeneous group of patients who suffered persistent, noninvasive
         <em>
          Candida
         </em>
         infections of the skin, mucous membranes, and nails, as well as autoimmune manifestations, most commonly involving the endocrine system [
         <a href="#rid1">
          1-5
         </a>
         ]. The classic forms of CMCC are caused by pathogenic variants in the autoimmune regulator gene (
         <em>
          AIRE
         </em>
         ) and signal transducer and activator of transcription 1 gene (
         <em>
          STAT1
         </em>
         )  (
         <a class="graphic graphic_figure graphicRef117876" href="/z/d/graphic/117876.html" rel="external">
          figure 1
         </a>
         ).
        </p>
        <p>
         Classic CMCC is associated with a variety of additional clinical features:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Autoimmune manifestations other than endocrinopathy, including autoimmune hemolytic anemia, immune thrombocytopenia purpura, autoimmune neutropenia, and rheumatoid arthritis [
         <a href="#rid6">
          6,7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Various degrees of bone marrow failure with aplastic anemia [
         <a href="#rid8">
          8,9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Neoplastic diseases, mostly involving the mouth and esophagus, and benign and malignant thymomas [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Multiple abnormalities in the immune system including abnormal in vitro T cell proliferation to
         <em>
          Candida
         </em>
         antigen, humoral deficiencies, and increased susceptibility to bacterial and viral infections. (See
         <a class="local">
          'Laboratory evaluation'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H571991">
         <span class="h2">
          Autoimmune regulator deficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         Autoimmune regulator (AIRE) deficiency accounts for the majority of CMCC cases in distinct populations, such as the Finns and Sardinians, but only 20 to 40 percent of cases in other populations [
         <a href="#rid11">
          11
         </a>
         ]. It is detected at a frequency of 1:9000 in Iranian Jews, 1:14,500 in Sardinians, and 1:25,000 in Finns. The
         <em>
          AIRE
         </em>
         gene is localized to chromosome 21q 22.3 [
         <a href="#rid12">
          12
         </a>
         ]. The condition is transmitted in an autosomal recessive manner. More than 50 mutations have been described so far, with the most common mutation being R257X in the Finnish population.
        </p>
        <p>
         Patients suffer chronic candidiasis as well as autoimmune polyendocrinopathy, most commonly hypoparathyroidism and adrenal insufficiency, and skin dystrophy, hence the name given to this disorder: autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) (MIM #240300). The disorder is also referred to as autoimmune polyendocrine syndrome type I (APS-I or APS1).
        </p>
        <p class="headingAnchor" id="H10714680">
         <span class="h3">
          Pathogenesis of AIRE deficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         Random rearrangement of antigen-specific receptor genes during lymphocyte maturation produces a diverse repertoire of receptors including some able to recognize the body's own antigens. To prevent autoimmunity, thymocytes expressing self-reactive T cell receptors (TCRs) are eliminated. This selection process is primarily mediated by stromal cells in the thymus that purge the repertoire of self-reactive TCRs [
         <a href="#rid13">
          13
         </a>
         ]. A subpopulation of stromal cells, called medullary thymic epithelial cells (mTECs) [
         <a href="#rid14">
          14
         </a>
         ], express a vast spectrum of peripheral tissue autoantigens. mTECs present these antigens to differentiating T cells, and only the cells that recognize the autoantigens with high affinity are clonally deleted [
         <a href="#rid15">
          15
         </a>
         ]. Expression of many of these autoantigens is regulated by the transcription factor, AIRE [
         <a href="#rid15">
          15,16
         </a>
         ]. Abnormal AIRE results in impaired clonal deletion, thus allowing T cells expressing autoreactive TCRs to expand to the periphery and induce autoimmunity [
         <a href="#rid17">
          17,18
         </a>
         ]. AIRE transcripts have also been detected in secondary lymphoid organs, including monocyte/dendritic cells [
         <a href="#rid19">
          19
         </a>
         ] and radiosensitive lymph node stromal cells [
         <a href="#rid20">
          20
         </a>
         ]. Together, central and peripherally located AIRE are thought to play complementary roles in maintaining self-tolerance.
        </p>
        <p>
         Pathogenic variants in the
         <em>
          AIRE
         </em>
         gene lead to multiorgan autoimmunity [
         <a href="#rid18">
          18
         </a>
         ]. The endocrine system is most commonly involved. The severity of the inflammation and the organs/systems targeted vary with genetic background (human leukocyte antigen [HLA]-DR). As examples, HLA-DRB1*15-DQB1*0602 appears protective against type 1 diabetes mellitus [
         <a href="#rid21">
          21,22
         </a>
         ], while HLA-DRB1*04-DQB1*0302 is associated with alopecia and HLA-DRB1*DQ1*0602 is associated with adrenal failure [
         <a href="#rid23">
          23
         </a>
         ]. Autoimmunity is associated with increased levels of autoantibodies against proteins made specifically by the affected organs [
         <a href="#rid24">
          24,25
         </a>
         ]. Deletion of B cells with anti-CD20 antibody resulted in improvement of autoimmunity in AIRE-deficient mice, suggesting that antigen presentation by B cells and autoantibodies are important in the pathogenesis of CMCC [
         <a href="#rid26">
          26
         </a>
         ]. While success of
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         treatment was demonstrated in patients with pulmonary disease [
         <a href="#rid27">
          27
         </a>
         ] and type 1 diabetes mellitus [
         <a href="#rid28">
          28
         </a>
         ] associated with AIRE deficiency, its application in autoimmune tubulointerstitial nephritis has had mixed results so far [
         <a href="#rid29">
          29,30
         </a>
         ].
        </p>
        <p>
         Autoantibodies against interleukin (IL) 17 and IL-22 were identified in the serum of patients with AIRE deficiency, suggesting that susceptibility to
         <em>
          Candida
         </em>
         infections also has an autoimmune basis [
         <a href="#rid31">
          31-33
         </a>
         ]. One study suggested that IL-17A autoantibodies were correlated with disease severity [
         <a href="#rid34">
          34
         </a>
         ]. Another study found impaired T helper cell type 17 (Th17) responses to
         <em>
          Candida
         </em>
         in patients with AIRE deficiency and other types of CMCC [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
         Susceptibility to candidal infections in patients with AIRE deficiency may result from both abnormal adaptive and innate immunity. Dectin-1 is a beta-glucan receptor involved in the innate immune response to candidal infection. AIRE associates with components of the Dectin-1 signaling pathway, including Dectin-1, Syk, and caspase recruitment domain-containing protein 9 (CARD9) [
         <a href="#rid36">
          36
         </a>
         ]. The trace constitutive association increases with stimulation of the Dectin-1 pathway, resulting in production of tumor necrosis factor (TNF) alpha. TNF-alpha production after stimulation of the Dectin-1 pathway is reduced in patients with AIRE deficiency. (See
         <a class="local">
          'Dectin-1 deficiency'
         </a>
         below and
         <a class="local">
          'Differential diagnosis'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H571998">
         <span class="h3">
          Clinical features of AIRE deficiency/APECED
         </span>
         <span class="headingEndMark">
          —
         </span>
         AIRE deficiency/autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) is known for its wide variation in clinical presentation and course of disease, even among affected family members carrying an identical genetic aberration [
         <a href="#rid11">
          11,37,38
         </a>
         ]. This clinical heterogeneity can lead to a significant delay in diagnosis [
         <a href="#rid39">
          39
         </a>
         ]. The first manifestation of the disease can start between the ages of two months to &gt;18 years of age [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
         The classic triad is mucocutaneous candidiasis, hypoparathyroidism, and adrenal failure [
         <a href="#rid37">
          37
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chronic, or sometimes recurrent, candidal infection of the oral cavity, nails, and skin, and less frequently the esophagus, vagina, and gastrointestinal tract, is the presenting feature in 60 percent of patients and affects all patients by the time they are 40 years old. Skin lesions are frequently raised and sometimes disfiguring. Similarly, affected nail beds result in structurally malformed nails. These changes are probably due to a combination of infection and an exaggerated inflammatory (autoimmune) response  (
         <a class="graphic graphic_picture graphicRef59947" href="/z/d/graphic/59947.html" rel="external">
          picture 1
         </a>
         and
         <a class="graphic graphic_picture graphicRef71698" href="/z/d/graphic/71698.html" rel="external">
          picture 2
         </a>
         ).
         <em>
          Candida albicans
         </em>
         is the most common species to cause infection.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypoparathyroidism is the most common endocrine abnormality in this disease and the second most common feature in AIRE deficiency, occurring at presentation in approximately 30 percent of patients. More than 80 percent of patients are eventually afflicted. Hypoparathyroidism appears earlier and is more common in females than males. The resultant hypocalcemia and hypomagnesemia are sometimes hard to control and may lead to seizures.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adrenal failure is the third most common feature in the disease. It occurs in only approximately 5 percent at presentation but occurs in more than 60 percent of cases by the age of 15 years.
        </p>
        <p>
        </p>
        <p>
         Other manifestations are less common [
         <a href="#rid37">
          37,38
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other endocrinopathies include type 1 diabetes mellitus, hypothyroidism, growth hormone deficiency, Addison's disease, ovarian failure (appears to coexist with adrenal failure), and male hypogonadism.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other autoimmune manifestations include vitiligo and alopecia areata, which affects more than 30 percent of patients after the age of 20 years and can progress to universal baldness. Pernicious anemia affects more than 20 percent of patients after the age of 30 years. Hepatitis is rare.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Complications presumed due to chronic
         <em>
          Candida
         </em>
         infection include keratoconjunctivitis, which may lead to blindness, esophageal stricture, and squamous cell carcinoma of the mouth and esophagus [
         <a href="#rid40">
          40,41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Antibody deficiency to polysaccharide antigens may occur.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other oral and gastrointestinal manifestations include enamel abnormalities, chronic diarrhea, and constipation [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other ocular features reported include cortical lenticular opacities and chronic iridocyclitis [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pulmonary disease, interstitial nephritis, and encephalopathy may also occur [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         AIRE deficiency may also present with unusual features [
         <a href="#rid37">
          37
         </a>
         ]. Young children, even in their first year of life, may present with fever and periodic rash, dry eyes [
         <a href="#rid42">
          42
         </a>
         ], exocrine pancreatic insufficiency [
         <a href="#rid43">
          43
         </a>
         ], or renal involvement, including hypokalemia, hypertension, or tubular interstitial nephritis [
         <a href="#rid44">
          44,45
         </a>
         ].
        </p>
        <p>
         Forty to 80 percent of patients in North America present with clinical features uncommon in European cohorts, including urticaria, enteritis, pneumonitis, and Sjögren-like syndrome [
         <a href="#rid46">
          46
         </a>
         ]. This is most likely due to the predominance of a Scandinavian founder mutation in this population.
        </p>
        <p class="headingAnchor" id="H3723844046">
         <span class="h2">
          Signal transducer and activator of transcription (STAT1) dysfunction
         </span>
         <span class="headingEndMark">
          —
         </span>
         STAT1 is a critical transcription factor downstream of interferon (IFN) receptor signaling. Upon ligation of IFN-gamma to its receptor, Janus kinase (JAK) 1/2 tyrosine kinases are activated, leading to phosphorylation of the receptor, docking and dimerization of STAT1 molecules, and release of dimerized STAT1. Once dimerized STAT1 translocates to the nucleus, it binds to recognized sites and subsequently drives IFN-triggered gene transcription of antiviral and proinflammatory proteins [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
         Monoallelic mutations in the
         <em>
          STAT1
         </em>
         gene were first identified in a cohort of patients with presumed autosomal dominant CMCC [
         <a href="#rid48">
          48
         </a>
         ]. The proposed mechanism of these mutations is a gain of function caused by impaired nuclear dephosphorylation of STAT1 [
         <a href="#rid49">
          49-53
         </a>
         ]. These events lead to impaired IFN-mediated gene expression [
         <a href="#rid54">
          54
         </a>
         ]. STAT1 gain-of-function mutations frequently result in decreased production of IFN-gamma, IL-17, and IL-22, suggesting a defect in T helper cell type 1 (Th1) and Th17 responses [
         <a href="#rid55">
          55
         </a>
         ]. Other immune aberrations reported in these patients include progressive lymphopenia, reduced responses to mitogens and antigens [
         <a href="#rid56">
          56
         </a>
         ], hypogammaglobulinemia [
         <a href="#rid52">
          52,56,57
         </a>
         ], and impaired natural killer (NK) cell function [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
         The clinical spectrum of manifestations in patients with STAT1 dysfunction is wide but most commonly includes oral thrush as well as fungal skin and nail infections [
         <a href="#rid48">
          48,57,59
         </a>
         ]. Microbial infections including sinusitis, pneumonia, and folliculitis are also common [
         <a href="#rid60">
          60,61
         </a>
         ]. Viral infections with herpes viruses, papillomavirus, and JC virus are less common. However, these viral infections can be life threatening in a subset of patients who gradually develop a profound combined immunodeficiency that may also predispose them to invasive fungal infections such as coccidioidomycosis, histoplasmosis, and mucormycosis [
         <a href="#rid49">
          49-51,56,60,62,63
         </a>
         ].
        </p>
        <p>
         Up to half of patients with STAT1 dysfunction have hypothyroidism, inflammatory bowel disease (IBD)-like disease, or autoimmune cytopenias [
         <a href="#rid56">
          56,60
         </a>
         ]. Rarely, some patients suffer severe and repeated strokes caused by cerebral vasculitis and multiple aneurysms, mainly in medium-size vessels (Moyamoya-like disease) [
         <a href="#rid48">
          48,52,53,60,64
         </a>
         ].
        </p>
        <p>
         Patients with severe cutaneous involvement have an increased risk of developing skin cancer [
         <a href="#rid52">
          52
         </a>
         ]. Other patients with a progressive decline in immunity are at increased risk of developing chronic lung disease or overwhelming viral or fungal infections.
        </p>
        <p>
         Other
         <em>
          STAT1
         </em>
         mutations that cause loss of expression and loss of function produce different phenotypes, such as susceptibility to mycobacterial and viral infections or combined immunodeficiency. (See
         <a class="medical medical_review" href="/z/d/html/3958.html" rel="external">
          "Mendelian susceptibility to mycobacterial diseases: Specific defects", section on 'STAT1 defects'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3935.html" rel="external">
          "Combined immunodeficiencies: An overview"
         </a>
         and
         <a class="local">
          'Laboratory evaluation'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2390454011">
         <span class="h1">
          IL-17 PATHWAY IMMUNE DEFICIENCIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         T cell immunity is critical for host defense against superficial as well as invasive fungal infections. A deficit in interleukin (IL) 17-producing T cell is associated with a growing number of conditions characterized by a susceptibility to bacterial and fungal infections [
         <a href="#rid65">
          65
         </a>
         ]. There are six IL-17 cytokines (IL-17 A through F) that bind to five distinct receptors (IL-17 RA through RE). These receptors form homodimers or heterodimers in combinations that recognize a distinct cytokine. Ligation of these receptors induces the recruitment of the adaptor ACT1 (nuclear factor kappa-B activator 1, also called TRAF3-interacting protein 2 [TRAF3IP2]), which is required for downstream signaling  (
         <a class="graphic graphic_figure graphicRef117876" href="/z/d/graphic/117876.html" rel="external">
          figure 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/3980.html" rel="external">
          "The adaptive cellular immune response: T cells and cytokines", section on 'Th17'
         </a>
         .)
        </p>
        <p>
         Mutations in the genes for IL-17RA, IL-17RC, IL-17F, and ACT1 are all associated with various degrees of mucocutaneous candidiasis. Their phenotype is not strictly limited to superficial
         <em>
          Candida
         </em>
         infections, and, frequently, their more prominent features are severe infections with
         <em>
          Staphylococcus aureus
         </em>
         or
         <em>
          Mycobacteria
         </em>
         [
         <a href="#rid65">
          65,66
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3685378508">
         <span class="h2">
          IL-17RA deficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         Interleukin 17 receptor alpha (IL-17RA) is the common subunit for all five members of the IL-17R family [
         <a href="#rid67">
          67
         </a>
         ]. Most patients described so far with autosomal recessive IL-17RA deficiency are of Middle Eastern, Japanese, or South American origins. Analysis of a large cohort of 21 patients revealed that oral thrush was present in all patients followed by scalp and skin
         <em>
          Candida
         </em>
         infections. Nail involvement was recorded in only approximately 20 percent of these patients. Staphylococcal skin infections in the forms of pustules, folliculitis, and furunculosis were prevalent. Other infections included pneumonia sinusitis, otitis, and pulmonary tuberculosis. Eczema was also reported in some patients.
        </p>
        <p class="headingAnchor" id="H2993051645">
         <span class="h2">
          IL-17RC deficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         A few patients of Turkish descent with homozygous mutations in interleukin 17 receptor C (IL-17RC) have been reported. Patients presented at a young age predominantly with oral candidiasis and pustular skin lesions [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2124802618">
         <span class="h2">
          IL-17F deficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mucosal candidiasis was found in several members of an extended family from Argentina. Affected individuals were found to carry a heterozygous mutation in the interleukin 17F (
         <em>
          IL17F
         </em>
         ) gene, suggesting autosomal dominant inheritance. However, two healthy individuals in this family had an identical monoallelic variant [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2995902895">
         <span class="h2">
          ACT1 deficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         Two adult siblings born to consanguineous Algerian parents were reported to have homozygous mutations in the
         <em>
          ACT1
         </em>
         (nuclear factor kappa-B activator 1, also called TRAF3-interacting protein 2 [TRAF3QP2]) gene. One patient suffered macro-cheilitis, while his sibling had
         <em>
          S. aureus
         </em>
         blepharitis and folliculitis. Both had repeated episodes of oral thrush [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H10715373">
         <span class="h1">
          OTHER GENETIC DEFECTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other genetic aberrations are associated with far smaller numbers of cases and are frequently found in a single family. These genetic defects are all disease modifiers. In some cases, inheritance may involve the effect of multiple genes, as is seen in some patients with lymphoid phosphatase (Lyp) [
         <a href="#rid70">
          70
         </a>
         ] and Dectin-1 [
         <a href="#rid71">
          71
         </a>
         ] mutations.
        </p>
        <p class="headingAnchor" id="H572091">
         <span class="h2">
          Lyp mutation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The protein tyrosine phosphatase nonreceptor-type 22 (
         <em>
          PTPN22
         </em>
         ) gene localized to 1p13 encodes Lyp [
         <a href="#rid72">
          72
         </a>
         ]. The substrates of Lyp include the kinases Lck, Fyn, Zap-70, and the CD3-zeta chain of the T cell receptor (TCR) [
         <a href="#rid73">
          73
         </a>
         ]. In accordance with this observation, Lyp overexpression downregulates TCR signaling, while Lyp deficiency enhances T cell activation. Lyp also interacts with the Src family negative regulatory kinase, Csk. Lyp and Csk act in tandem to negatively regulate activation of Src kinases [
         <a href="#rid74">
          74
         </a>
         ]. The interaction between Lyp and Csk is lost in the R620W mutation of Lyp since the arginine at this position is necessary for Csk-SH3 domain recognition of protein-rich areas of Lyp. This mutation is also believed to result in gain of function that alters TCR signaling, resulting in possible compromised central as well as peripheral tolerance [
         <a href="#rid75">
          75,76
         </a>
         ]. This variant probably acts as a disease modifier, altering expression of another gene, although this gene is not known.
        </p>
        <p>
         Six patients with CMCC who carried a R620W mutation of
         <em>
          PTPN22
         </em>
         all had oral or skin candidiasis, similar to patients with
         <em>
          AIRE
         </em>
         mutations, but none had enamel defects [
         <a href="#rid70">
          70
         </a>
         ]. The most common endocrine abnormalities were hypothyroidism and gonadal failure. None had hypoparathyroidism, the most common endocrine abnormality in autoimmune regulator (AIRE) deficiency. A unique finding seen in five of the patients with the R620W Lyp mutant was chronic lung disease, including bronchiectasis. This is probably due to antibody deficiency in four of the six patients, another manifestation almost nonexistent in AIRE deficiency. The R620W mutant is also associated with a variety of autoimmune disorders including rheumatoid arthritis, type 1 diabetes, systemic lupus erythematosus (SLE), and Addison's disease [
         <a href="#rid77">
          77-84
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H572040">
         <span class="h2">
          Dectin-1 deficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          C. albicans
         </em>
         is recognized by the innate immune system through pattern-recognition receptors, such as the toll-like receptors (TLRs) and lectin-like receptors [
         <a href="#rid85">
          85
         </a>
         ]. TLR2, TLR4, and mannose receptors recognize mannans,
         <em>
          Candida
         </em>
         cell wall components [
         <a href="#rid71">
          71,85-87
         </a>
         ]. These receptors collaborate with the beta-glucan receptor Dectin-1 (MIM *606264) in stimulation of cytokine production [
         <a href="#rid88">
          88
         </a>
         ]. Dectin-1 enhances TLR2 and TLR4 induced cytokine production, such as tumor necrosis factor (TNF). In its absence, mice have increased susceptibility to
         <em>
          C. albicans
         </em>
         and
         <em>
          Pneumocystis jirovecii
         </em>
         infections [
         <a href="#rid89">
          89,90
         </a>
         ].
        </p>
        <p>
         A family with Dectin-1 deficiency was identified in which affected members had a homozygous single nucleotide polymorphism (SNP) in exon 6 that caused a change of amino acid 238 from tyrosine to a stop codon [
         <a href="#rid71">
          71
         </a>
         ]. These patients suffered vulvovaginitis and onychomycosis but did not have invasive candidiasis, other major infections, or autoimmune manifestations. It therefore appears that Dectin-1 deficiency leads to a pure susceptibility to mucosal and skin, but not invasive, fungal infection. However, the allelic frequency of these Dectin-1 variants are common and therefore probably represent modifying or predisposing variants rather than directly pathogenic variants.
        </p>
        <p class="headingAnchor" id="H10677880">
         <span class="h2">
          Toll-like receptor 3 defect (L412F mutant)
         </span>
         <span class="headingEndMark">
          —
         </span>
         TLR3 plays a role in initiating adaptive immune responses, suppressing autoimmune disorders, and protecting against viral infection. Fourteen patients with no identified mutations in the other genes known to cause CMCC were found to carry the
         <em>
          TLR3
         </em>
         L412F mutant that renders TLR3 dysfunctional [
         <a href="#rid91">
          91
         </a>
         ]. This variant probably acts as a disease modifier, although the modified gene is unknown. These patients were previously classified as a distinct clinical subgroup, CMCC with autoimmunity and combined immunodeficiency.
        </p>
        <p>
         The one patient who was homozygous for this variant had more severe disease with treatment-resistant oral and esophageal candidiasis; cytomegalovirus (CMV)-induced hepatitis, viremia, and pneumonitis; recurrent sinopulmonary infections; chronic lung disease with bronchiectasis; and thrombocytopenia, hemolytic anemia, and neutropenia.
        </p>
        <p>
         Patients heterozygous for the TLR3 variant all had chronic candidiasis, and most had nail dystrophy, similar to other forms of CMCC. However, these patients also had severe chronic infections (mainly sinopulmonary), often leading to chronic lung disease and bronchiectasis. In addition, they had a high frequency of severe viral infections, particularly CMV, autoimmune disorders (eg, cytopenias), and endocrine abnormalities (eg, hypothyroidism). Rarely, these patients develop bone marrow failure, possibly due to CMV infections.
        </p>
        <p>
         Immune evaluation reveals antibody deficiency as well as abnormal in vitro proliferative responses to mitogens. Interferon (IFN) gamma production was decreased in response to stimulation with a TLR3 ligand.
        </p>
        <p class="headingAnchor" id="H358468207">
         <span class="h2">
          ROR-gamma t deficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         Retinoic acid-binding receptor-related orphan receptor gamma (ROR-gamma t) is a transcription factor that regulates the T helper type 17 (Th17) subset. Biallelic loss-of-function mutations in the
         <em>
          RORC
         </em>
         gene were identified in seven patients from three unrelated kindreds [
         <a href="#rid92">
          92
         </a>
         ]. These patients presented with both CMCC and disseminated Bacillus Calmette-Guérin (BCG) infection. Interleukin (IL) 17 producing cells were absent in these patients, and there was an impaired leukocyte response to
         <em>
          Mycobacterium
         </em>
         due to a defect in IFN-gamma production by circulating T cells.
        </p>
        <p class="headingAnchor" id="H29999189">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of CMCC is primarily based upon clinical features including chronic, noninvasive candidiasis of the skin and mucous membranes associated with autoimmune manifestations, most commonly endocrinopathies. Most patients are diagnosed during childhood, but some are not identified until adulthood. If a STAT1 defect is suspected, STAT1 function should be tested in freshly obtained peripheral blood lymphocytes. The diagnosis is confirmed by identifying a disease-causing mutation  (
         <a class="graphic graphic_figure graphicRef117876" href="/z/d/graphic/117876.html" rel="external">
          figure 1
         </a>
         ). If interleukin (IL) 17 pathway-related defects are suspected but the significance of the genetic abnormalities is unclear, evaluation of cytokine function and cytokine receptor responses may clinically be valuable. (See
         <a class="local">
          'Classic forms of CMCC with associated autoimmunity'
         </a>
         above and
         <a class="local">
          'IL-17 pathway immune deficiencies'
         </a>
         above and
         <a class="local">
          'Other genetic defects'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H29999197">
         <span class="h1">
          LABORATORY EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients with chronic candidiasis should be evaluated for a suspected primary immunodeficiency. This should include a complete blood count with differential; immunoglobulin levels including immunoglobulin E (IgE) level; T, B, and natural killer (NK) cell subsets; and T cell function. (See
         <a class="medical medical_review" href="/z/d/html/3903.html" rel="external">
          "Laboratory evaluation of the immune system"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5949.html" rel="external">
          "Approach to the child with recurrent infections"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3908.html" rel="external">
          "Approach to the adult with recurrent infections"
         </a>
         .)
        </p>
        <p>
         The only definitive laboratory test for the diagnosis of CMCC is the genetic analysis of relevant genes. However, autoantibodies against interferon (IFN) alpha and IFN-omega are consistently high in patients with AIRE mutations [
         <a href="#rid93">
          93,94
         </a>
         ]. Measurement of autoantibodies against IFN-omega and well as interleukin (IL) 17A, IL-17F, and IL-22 can help differentiate CMCC due to genetic causes from autoimmune mimics. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         below.)
        </p>
        <p>
         Other laboratory findings are less definitive but can aid in the diagnosis. These include standard laboratory tests to evaluate for endocrine disorders, such as hypoparathyroidism and adrenal insufficiency that are associated with CMCC. A blood count can reveal anemia, either due to iron deficiency (hypochromic, microcytic) or due to vitamin B12 deficiency (megaloblastic). Both may be caused by malabsorption and parietal cell atrophy. Liver function should also be screened because hepatitis is rarely associated with CMCC.
        </p>
        <p>
         Evaluation of the immune system may identify a selective inability to respond in vitro (T cell proliferation) or in vivo (cutaneous delayed-type hypersensitivity) to
         <em>
          Candida
         </em>
         , especially in patients with AIRE deficiency [
         <a href="#rid95">
          95
         </a>
         ]. In other patients, lymphopenia and more extensive abnormalities in in vitro antigenic and mitogenic responses are identified. In one cohort, 20 percent of patients with non-autoimmune regulator (AIRE) deficiency CMCC had reduced number and/or function of circulating T cells [
         <a href="#rid96">
          96
         </a>
         ]. Patients with
         <em>
          STAT1
         </em>
         mutation in the DNA-binding domain may have a gradual decline of T, B, and NK cells [
         <a href="#rid58">
          58
         </a>
         ], as well as deteriorating T cell function.
        </p>
        <p>
         Humoral immunity may also be affected in patients with non-AIRE deficiency CMCC and includes low immunoglobulin G2 (IgG2) and IgG4, hypogammaglobulinemia, and an inadequate response to vaccination with polysaccharide antigens (eg, unconjugated pneumococcal vaccine) [
         <a href="#rid56">
          56,97,98
         </a>
         ].
        </p>
        <p>
         Serum
         <em>
          Candida
         </em>
         antibodies are not of value in the diagnosis of CMCC, nor are skin or serum IgE tests for
         <em>
          Candida
         </em>
         .
        </p>
        <p class="headingAnchor" id="H572069">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chronic candidiasis can be encountered in many types of primary immunodeficiencies. Most commonly, profound primary or secondary T cell deficiencies predispose to susceptibility to
         <em>
          Candida
         </em>
         . Patients with severe combined immunodeficiency (SCID) and acquired immunodeficiency almost invariably present with oral thrush and/or with other cutaneous
         <em>
          Candida
         </em>
         infections. However, unlike patients with CMCC,
         <em>
          Candida
         </em>
         infections in these disorders can become invasive with systemic spread. (See
         <a class="medical medical_review" href="/z/d/html/3955.html" rel="external">
          "Severe combined immunodeficiency (SCID): An overview"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3912.html" rel="external">
          "Severe combined immunodeficiency (SCID): Specific defects"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3939.html" rel="external">
          "Secondary immunodeficiency induced by biologic therapies"
         </a>
         .)
        </p>
        <p>
         A number of other primary immunodeficiencies can result in candidiasis, but common to all of these conditions is the presence of other major clinical features not present in CMCC [
         <a href="#rid99">
          99
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Caspase recruitment domain-containing protein 9 (CARD9) plays a positive regulatory role in cell apoptosis and nuclear factor (NF)-kappa B activation and is involved in antifungal immunity [
         <a href="#rid100">
          100
         </a>
         ]. Autosomal recessive forms of CARD9 deficiency, a phagocytic disorder with variable presentation, have been identified in several kindreds and individual patients [
         <a href="#rid101">
          101-106
         </a>
         ]. Manifestations include meningoencephalitis and invasive brain infections due to
         <em>
          Candida
         </em>
         species, CMCC, disseminated infections with
         <em>
          Exophiala
         </em>
         and
         <em>
          Phialophora
         </em>
         species, superficial (cutaneous) dermatophytosis, and deep dermatophytosis with involvement of the skin, scalp, nails, lymph nodes, and brain. Multifocal-to-coalescing granulomatous dermatitis is seen on skin biopsy in patients with deep dermatophytosis. CARD9 levels (measured by flow cytometry) in monocyte-derived dendritic cells are low to absent, depending upon the specific mutation. The specific mechanisms underlying increased susceptibility to fungal disease in these patients remain unclear.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CD25 deficiency can cause persistent oral and esophageal candidiasis. However, patients also have a variable array of other manifestations, including bacterial, viral, and other fungal infections; enteropathy; primary biliary cholangitis; and eczema. (See
         <a class="medical medical_review" href="/z/d/html/3924.html" rel="external">
          "IPEX: Immune dysregulation, polyendocrinopathy, enteropathy, X-linked", section on 'IPEX-like syndromes'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with hyperimmunoglobulin E (hyper-IgE) syndrome due to signal transducer and activator of transcription 3 (
         <em>
          STAT3
         </em>
         ) mutation frequently have mucocutaneous candidiasis as a result of impaired T helper cell type 17 (Th17) function [
         <a href="#rid107">
          107-109
         </a>
         ]. However, deep staphylococcal abscesses,
         <em>
          Aspergillus
         </em>
         infections, and dysmorphic features are also prominent features. (See
         <a class="medical medical_review" href="/z/d/html/3960.html" rel="external">
          "Autosomal dominant hyperimmunoglobulin E syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dedicator of cytokinesis 8 (DOCK8) deficiency can cause mucocutaneous candidiasis but is also associated with recurrent respiratory tract infections, cutaneous viral infections,
         <em>
          S. aureus
         </em>
         skin infections, atopic disease, hepatic disorders, and cancer, along with eosinophilia and elevated IgE [
         <a href="#rid110">
          110
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/141326.html" rel="external">
          "Combined immunodeficiencies: Specific defects", section on 'DOCK8 deficiency'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ataxia-telangiectasia can also present with oral thrush, but these patients also develop neurologic abnormalities including progressive cerebellar ataxia and abnormal eye movements, as well as oculocutaneous telangiectasias [
         <a href="#rid109">
          109
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6233.html" rel="external">
          "Ataxia-telangiectasia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The primary manifestations in patients with interleukin (IL) 12 receptor beta1 (
         <em>
          IL12RB1
         </em>
         ) mutations are disseminated
         <em>
          Salmonella
         </em>
         and nontuberculous mycobacterial (NTM) infections or disseminated Bacillus Calmette-Guérin (BCG) infection. These patients can also have oral candidiasis, although, unlike typical cases of CMCC, few have esophageal involvement, cutaneous lesions are rare, and some patients have disseminated candidiasis [
         <a href="#rid111">
          111
         </a>
         ]. The majority have risk factors for candidal infections, such as antibiotic treatment for mycobacterial infections. To a lesser degree, some patients with IL-12p40 deficiency, another disorder with increased susceptibility to mycobacterial disease, have either oral thrush or disseminated candidiasis [
         <a href="#rid112">
          112
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3958.html" rel="external">
          "Mendelian susceptibility to mycobacterial diseases: Specific defects"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3958.html" rel="external">
          "Mendelian susceptibility to mycobacterial diseases: Specific defects", section on 'IL-12 p40 deficiency'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Autoimmune disease can mimic the genetic causes of CMCC. Autoantibodies against IL-17A, IL-17F, and IL-22 produced by Th17 cells have been identified in thymoma patients with CMCC [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
         Chronic candidiasis is also seen in patients with diabetes mellitus, human immunodeficiency virus (HIV) infection, or in patients treated with systemic or inhaled glucocorticoids [
         <a href="#rid113">
          113
         </a>
         ] or prolonged courses of antibiotics [
         <a href="#rid114">
          114
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3986.html" rel="external">
          "Glucocorticoid effects on the immune system"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H572076">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Management includes antifungal therapy and treatment of associated endocrine and autoimmune abnormalities.
        </p>
        <p>
         Candidiasis usually clears with treatment with a member of the azole family, although chronic suppressive therapy is often required to prevent recurrences [
         <a href="#rid115">
          115-117
         </a>
         ].
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          Fluconazole
         </a>
         is the preferred treatment. It has good activity against
         <em>
          C. albicans
         </em>
         , is easy to administer, has few side effects, and is relatively inexpensive. Drug resistance may occur with suppressive therapy [
         <a href="#rid118">
          118
         </a>
         ]. The dose can be escalated if increasing resistance is an issue, but ultimately another azole agent will need to be used.
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          Itraconazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         , or
         <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">
          posaconazole
         </a>
         can be tried, in that order. Liver function should be carefully monitored while patients are on systemic therapy with these drugs. Amphotericin has been successfully used in severe cases [
         <a href="#rid119">
          119
         </a>
         ]. Antifungal therapy for mucocutaneous candidiasis is discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2432.html" rel="external">
          "Oropharyngeal candidiasis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/495.html" rel="external">
          "Pharmacology of azoles"
         </a>
         .)
        </p>
        <p>
         Endocrine abnormalities should be treated with replacement therapy, when possible [
         <a href="#rid37">
          37,114
         </a>
         ]. In cases of hypoparathyroidism, calcium levels should be carefully monitored, and calcium supplementation should be given. Frequently, magnesium must be given to avoid seizures that can be caused by hypomagnesemia [
         <a href="#rid37">
          37
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/826.html" rel="external">
          "Treatment of hypocalcemia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/834.html" rel="external">
          "Hypomagnesemia: Evaluation and treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5825.html" rel="external">
          "Treatment of adrenal insufficiency in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/155.html" rel="external">
          "Treatment of adrenal insufficiency in adults"
         </a>
         .)
        </p>
        <p>
         Antibody deficiency, if severe, should be treated with
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         replacement [
         <a href="#rid97">
          97
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3911.html" rel="external">
          "Immune globulin therapy in inborn errors of immunity"
         </a>
         .)
        </p>
        <p>
         The experience in controlling severe autoimmune manifestations in CMCC is limited to single case reports that suggest potentially effective treatments:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          Prednisone
         </a>
         60 mg/day for two weeks was effective in resolving autoimmune panniculitis [
         <a href="#rid120">
          120
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          Prednisone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         , and
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil, which were given to prevent renal transplant rejection, reversed multiple autoimmune manifestations and reduced levels of autoantibodies [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          Prednisone
         </a>
         in combination with
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         was effective in improving autoimmune hepatitis [
         <a href="#rid11">
          11,21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severe malabsorption was reversed with a pulse of
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         followed by oral
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         maintenance therapy [
         <a href="#rid121">
          121
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Long-term clinical remission was reported after continuous therapy with granulocyte-colony stimulating factor (G-CSF) [
         <a href="#rid122">
          122
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Oral candidiasis and alopecia areata resolved on
         <a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">
          ruxolitinib
         </a>
         , an oral Janus kinase (Jak) family protein kinase inhibitor [
         <a href="#rid123">
          123
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Recurrent oral and esophageal
         <em>
          C. albicans
         </em>
         infections and oral and vaginal ulcers were prevented with
         <a class="drug drug_general" data-topicid="118052" href="/z/d/drug information/118052.html" rel="external">
          baricitinib
         </a>
         , an oral JAK 1/2 inhibitor [
         <a href="#rid124">
          124
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There are two reports of successful hematopoietic cell transplantation in patients with CMCC and severe autoimmune disease [
         <a href="#rid9">
          9,125
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Transplantation of thymus tissue [
         <a href="#rid126">
          126-128
         </a>
         ] and human leukocyte antigen (HLA)-matched peripheral blood leukocyte infusions [
         <a href="#rid129">
          129,130
         </a>
         ] were attempted therapies before effective oral antifungal drugs became available. Both showed limited and short-lived clinical improvement and are no longer used.
        </p>
        <p class="headingAnchor" id="H3251680964">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112831.html" rel="external">
          "Society guideline links: Inborn errors of immunity (previously called primary immunodeficiencies)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10714482">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical manifestations
         </strong>
         – Chronic mucocutaneous candidiasis (CMCC) is a heterogeneous group of syndromes with common features including chronic, noninvasive
         <em>
          Candida
         </em>
         infections of the skin, nails, and mucous membranes and associated autoimmune manifestations (most commonly endocrinopathies). (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genetics
         </strong>
         – CMCC is caused by genetic defects in the immune system, including those affecting autoimmune regulator (AIRE), signal transducer and activator of transcription 1 (STAT1), the interleukin (IL) 17 pathway, lymphoid phosphatase (Lyp), beta-glucan receptor Dectin-1, and Toll-like receptor 3 (TLR3). However, the genetic defect has not been identified in all patients, and inheritance may involve multiple genes in some cases. (See
         <a class="local">
          'Autoimmune regulator deficiency'
         </a>
         above and
         <a class="local">
          'IL-17 pathway immune deficiencies'
         </a>
         above and
         <a class="local">
          'Other genetic defects'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of CMCC is primarily based upon clinical features including chronic, noninvasive candidiasis of the skin and mucous membranes associated with autoimmune manifestations and can be confirmed in most patients by genetic testing. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnosis
         </strong>
         – The differential diagnosis of CMCC includes primary and secondary immunodeficiencies that affect T cell function, including combined immunodeficiencies, such as CD25 deficiency, and severe combined immunodeficiency (SCID). Chronic candidiasis is also seen in patients treated with systemic or inhaled glucocorticoids or prolonged courses of antibiotics. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         – Management includes antifungal therapy and treatment of associated endocrine and autoimmune abnormalities. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H126521516">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The editorial staff at UpToDate acknowledges E Richard Stiehm, MD, who contributed as a Section Editor to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Thorpe ES, Handley HE. Chronic tetany and chronic mycelia stomatitis in a child aged four and one half years. Am J Dis Child 1929; 38:228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           CRAIG JM, SCHIFF LH, BOONE JE. Chronic moniliasis associated with Addison's disease. AMA Am J Dis Child 1955; 89:669.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ESSELBORN VM, LANDING BH, WHITAKER J, WILLIAMS RR. The syndrome of familial juvenile hypoadrenocorticism, hypoparathyroidism and superficial moniliasis. J Clin Endocrinol Metab 1956; 16:1374.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           HUNG W, MIGEON CJ, PARROTT RH. A POSSIBLE AUTOIMMUNE BASIS FOR ADDISON'S DISEASE IN THREE SIBLINGS, ONE WITH IDIOPATHIC HYPOPARATHYROIDISM, PERNICIOUS ANEMIA AND SUPERFICIAL MONILIASIS. N Engl J Med 1963; 269:658.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blizzard RM, Gibbs JH. Candidiasis: studies pertaining to its association with endocrinopathies and pernicious anemia. Pediatrics 1968; 42:231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herrod HG. Chronic mucocutaneous candidiasis in childhood and complications of non-Candida infection: a report of the Pediatric Immunodeficiency Collaborative Study Group. J Pediatr 1990; 116:377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oyefara BI, Kim HC, Danziger RN, et al. Autoimmune hemolytic anemia in chronic mucocutaneous candidiasis. Clin Diagn Lab Immunol 1994; 1:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Twomey JJ, Waddell CC, Krantz S, et al. Chronic mucocutaneous candidiasis with macrophage dysfunction, a plasma inhibitor, and co-existent aplastic anemia. J Lab Clin Med 1975; 85:968.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deeg HJ, Lum LG, Sanders J, et al. Severe aplastic anemia associated with chronic mucocutaneous candidiasis. Immunologic and hematologic reconstitution after allogeneic bone marrow transplantation. Transplantation 1986; 41:583.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kirkpatrick CH, Windhorst DB. Mucocutaneous candidiasis and thymoma. Am J Med 1979; 66:939.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahonen P, Myllärniemi S, Sipilä I, Perheentupa J. Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. N Engl J Med 1990; 322:1829.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Finnish-German APECED Consortium. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. Nat Genet 1997; 17:399.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siggs OM, Makaroff LE, Liston A. The why and how of thymocyte negative selection. Curr Opin Immunol 2006; 18:175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heino M, Peterson P, Kudoh J, et al. Autoimmune regulator is expressed in the cells regulating immune tolerance in thymus medulla. Biochem Biophys Res Commun 1999; 257:821.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kyewski B, Klein L. A central role for central tolerance. Annu Rev Immunol 2006; 24:571.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson MS, Venanzi ES, Klein L, et al. Projection of an immunological self shadow within the thymus by the aire protein. Science 2002; 298:1395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson MS, Venanzi ES, Chen Z, et al. The cellular mechanism of Aire control of T cell tolerance. Immunity 2005; 23:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liston A, Lesage S, Wilson J, et al. Aire regulates negative selection of organ-specific T cells. Nat Immunol 2003; 4:350.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kogawa K, Nagafuchi S, Katsuta H, et al. Expression of AIRE gene in peripheral monocyte/dendritic cell lineage. Immunol Lett 2002; 80:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee JW, Epardaud M, Sun J, et al. Peripheral antigen display by lymph node stroma promotes T cell tolerance to intestinal self. Nat Immunol 2007; 8:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Betterle C, Greggio NA, Volpato M. Clinical review 93: Autoimmune polyglandular syndrome type 1. J Clin Endocrinol Metab 1998; 83:1049.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karvonen M, Viik-Kajander M, Moltchanova E, et al. Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group. Diabetes Care 2000; 23:1516.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Halonen M, Eskelin P, Myhre AG, et al. AIRE mutations and human leukocyte antigen genotypes as determinants of the autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy phenotype. J Clin Endocrinol Metab 2002; 87:2568.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Betterle C, Dal Pra C, Mantero F, Zanchetta R. Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. Endocr Rev 2002; 23:327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yu L, Brewer KW, Gates S, et al. DRB1*04 and DQ alleles: expression of 21-hydroxylase autoantibodies and risk of progression to Addison's disease. J Clin Endocrinol Metab 1999; 84:328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gavanescu I, Benoist C, Mathis D. B cells are required for Aire-deficient mice to develop multi-organ autoinflammation: A therapeutic approach for APECED patients. Proc Natl Acad Sci U S A 2008; 105:13009.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Popler J, Alimohammadi M, Kämpe O, et al. Autoimmune polyendocrine syndrome type 1: Utility of KCNRG autoantibodies as a marker of active pulmonary disease and successful treatment with rituximab. Pediatr Pulmonol 2012; 47:84.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kurozumi A, Okada Y, Arao T, et al. Induction of thyroid remission using rituximab in a patient with type 3 autoimmune polyglandular syndrome including Graves' disease and type 1 diabetes mellitus: a case report. Endocr J 2015; 62:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kluger N, Kataja J, Aho H, et al. Kidney involvement in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy in a Finnish cohort. Nephrol Dial Transplant 2014; 29:1750.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gwertzman R, Corey H, Roberti I. Autoimmune polyglandular syndrome type I can have significant kidney disease in children including recurrence in renal allograft - a report of two cases. Clin Nephrol 2016; 85:358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Puel A, Döffinger R, Natividad A, et al. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J Exp Med 2010; 207:291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kisand K, Bøe Wolff AS, Podkrajsek KT, et al. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J Exp Med 2010; 207:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Browne SK, Holland SM. Anticytokine autoantibodies in infectious diseases: pathogenesis and mechanisms. Lancet Infect Dis 2010; 10:875.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sarkadi AK, Taskó S, Csorba G, et al. Autoantibodies to IL-17A may be correlated with the severity of mucocutaneous candidiasis in APECED patients. J Clin Immunol 2014; 34:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ng WF, von Delwig A, Carmichael AJ, et al. Impaired T(H)17 responses in patients with chronic mucocutaneous candidiasis with and without autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J Allergy Clin Immunol 2010; 126:1006.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pedroza LA, Kumar V, Sanborn KB, et al. Autoimmune regulator (AIRE) contributes to Dectin-1-induced TNF-α production and complexes with caspase recruitment domain-containing protein 9 (CARD9), spleen tyrosine kinase (Syk), and Dectin-1. J Allergy Clin Immunol 2012; 129:464.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perheentupa J. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J Clin Endocrinol Metab 2006; 91:2843.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Capalbo D, Improda N, Esposito A, et al. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy from the pediatric perspective. J Endocrinol Invest 2013; 36:903.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mazza C, Buzi F, Ortolani F, et al. Clinical heterogeneity and diagnostic delay of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome. Clin Immunol 2011; 139:6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richman RA, Rosenthal IM, Solomon LM, Karachorlu KV. Candidiasis and multiple endocrinopathy. With oral squamous cell carcinoma complications. Arch Dermatol 1975; 111:625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosa DD, Pasqualotto AC, Denning DW. Chronic mucocutaneous candidiasis and oesophageal cancer. Med Mycol 2008; 46:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merenmies L, Tarkkanen A. Chronic bilateral keratitis in autoimmune polyendocrinopathy-candidiadis-ectodermal dystrophy (APECED). A long-term follow-up and visual prognosis. Acta Ophthalmol Scand 2000; 78:532.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ward L, Paquette J, Seidman E, et al. Severe autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy in an adolescent girl with a novel AIRE mutation: response to immunosuppressive therapy. J Clin Endocrinol Metab 1999; 84:844.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ulinski T, Perrin L, Morris M, et al. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome with renal failure: impact of posttransplant immunosuppression on disease activity. J Clin Endocrinol Metab 2006; 91:192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al-Owain M, Kaya N, Al-Zaidan H, et al. Renal failure associated with APECED and terminal 4q deletion: evidence of autoimmune nephropathy. Clin Dev Immunol 2010; 2010:586342.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferre EM, Rose SR, Rosenzweig SD, et al. Redefined clinical features and diagnostic criteria in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. JCI Insight 2016; 1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stark GR, Darnell JE Jr. The JAK-STAT pathway at twenty. Immunity 2012; 36:503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van de Veerdonk FL, Plantinga TS, Hoischen A, et al. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N Engl J Med 2011; 365:54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takezaki S, Yamada M, Kato M, et al. Chronic mucocutaneous candidiasis caused by a gain-of-function mutation in the STAT1 DNA-binding domain. J Immunol 2012; 189:1521.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sampaio EP, Hsu AP, Pechacek J, et al. Signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations and disseminated coccidioidomycosis and histoplasmosis. J Allergy Clin Immunol 2013; 131:1624.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uzel G, Sampaio EP, Lawrence MG, et al. Dominant gain-of-function STAT1 mutations in FOXP3 wild-type immune dysregulation-polyendocrinopathy-enteropathy-X-linked-like syndrome. J Allergy Clin Immunol 2013; 131:1611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu L, Okada S, Kong XF, et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med 2011; 208:1635.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maródi L, Cypowyj S, Tóth B, et al. Molecular mechanisms of mucocutaneous immunity against Candida and Staphylococcus species. J Allergy Clin Immunol 2012; 130:1019.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fujiki R, Hijikata A, Shirai T, et al. Molecular mechanism and structural basis of gain-of-function of STAT1 caused by pathogenic R274Q mutation. J Biol Chem 2017; 292:6240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meesilpavikkai K, Dik WA, Schrijver B, et al. A Novel Heterozygous Mutation in the STAT1 SH2 Domain Causes Chronic Mucocutaneous Candidiasis, Atypically Diverse Infections, Autoimmunity, and Impaired Cytokine Regulation. Front Immunol 2017; 8:274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharfe N, Nahum A, Newell A, et al. Fatal combined immunodeficiency associated with heterozygous mutation in STAT1. J Allergy Clin Immunol 2014; 133:807.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nahum A, Dalal I. Clinical manifestations associated with novel mutations in the coiled-coil domain of STAT1. LymphoSign Journal 2014; 1:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tabellini G, Vairo D, Scomodon O, et al. Impaired natural killer cell functions in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations. J Allergy Clin Immunol 2017; 140:553.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roifman CM. Monoallelic STAT1 mutations and disease patterns. LymphoSign Journal 2014; 1:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Depner M, Fuchs S, Raabe J, et al. The Extended Clinical Phenotype of 26 Patients with Chronic Mucocutaneous Candidiasis due to Gain-of-Function Mutations in STAT1. J Clin Immunol 2016; 36:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dotta L, Scomodon O, Padoan R, et al. Clinical heterogeneity of dominant chronic mucocutaneous candidiasis disease: presenting as treatment-resistant candidiasis and chronic lung disease. Clin Immunol 2016; 164:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kumar N, Hanks ME, Chandrasekaran P, et al. Gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation-related primary immunodeficiency is associated with disseminated mucormycosis. J Allergy Clin Immunol 2014; 134:236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Faitelson Y, Bates A, Shroff M, et al. A mutation in the STAT1 DNA-binding domain associated with hemophagocytic lymphohistocytosis. LymphoSign Journal 2014; 1:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grouhi M, Dalal I, Nisbet-Brown E, Roifman CM. Cerebral vasculitis associated with chronic mucocutaneous candidiasis. J Pediatr 1998; 133:571.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Puel A, Cypowyj S, Bustamante J, et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 2011; 332:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lévy R, Okada S, Béziat V, et al. Genetic, immunological, and clinical features of patients with bacterial and fungal infections due to inherited IL-17RA deficiency. Proc Natl Acad Sci U S A 2016; 113:E8277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okada S, Puel A, Casanova JL, Kobayashi M. Chronic mucocutaneous candidiasis disease associated with inborn errors of IL-17 immunity. Clin Transl Immunology 2016; 5:e114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ling Y, Cypowyj S, Aytekin C, et al. Inherited IL-17RC deficiency in patients with chronic mucocutaneous candidiasis. J Exp Med 2015; 212:619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boisson B, Wang C, Pedergnana V, et al. An ACT1 mutation selectively abolishes interleukin-17 responses in humans with chronic mucocutaneous candidiasis. Immunity 2013; 39:676.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nahum A, Bates A, Sharfe N, Roifman CM. Association of the lymphoid protein tyrosine phosphatase, R620W variant, with chronic mucocutaneous candidiasis. J Allergy Clin Immunol 2008; 122:1220.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferwerda B, Ferwerda G, Plantinga TS, et al. Human dectin-1 deficiency and mucocutaneous fungal infections. N Engl J Med 2009; 361:1760.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen S, Dadi H, Shaoul E, et al. Cloning and characterization of a lymphoid-specific, inducible human protein tyrosine phosphatase, Lyp. Blood 1999; 93:2013.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu J, Katrekar A, Honigberg LA, et al. Identification of substrates of human protein-tyrosine phosphatase PTPN22. J Biol Chem 2006; 281:11002.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gjörloff-Wingren A, Saxena M, Williams S, et al. Characterization of TCR-induced receptor-proximal signaling events negatively regulated by the protein tyrosine phosphatase PEP. Eur J Immunol 1999; 29:3845.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vang T, Congia M, Macis MD, et al. Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat Genet 2005; 37:1317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gregorieff A, Cloutier JF, Veillette A. Sequence requirements for association of protein-tyrosine phosphatase PEP with the Src homology 3 domain of inhibitory tyrosine protein kinase p50(csk). J Biol Chem 1998; 273:13217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bottini N, Musumeci L, Alonso A, et al. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet 2004; 36:337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bottini N, Vang T, Cucca F, Mustelin T. Role of PTPN22 in type 1 diabetes and other autoimmune diseases. Semin Immunol 2006; 18:207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Criswell LA, Pfeiffer KA, Lum RF, et al. Analysis of families in the multiple autoimmune disease genetics consortium (MADGC) collection: the PTPN22 620W allele associates with multiple autoimmune phenotypes. Am J Hum Genet 2005; 76:561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hinks A, Eyre S, Barton A, et al. Investigation of genetic variation across the protein tyrosine phosphatase gene in patients with rheumatoid arthritis in the UK. Ann Rheum Dis 2007; 66:683.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaufman KM, Kelly JA, Herring BJ, et al. Evaluation of the genetic association of the PTPN22 R620W polymorphism in familial and sporadic systemic lupus erythematosus. Arthritis Rheum 2006; 54:2533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kyogoku C, Langefeld CD, Ortmann WA, et al. Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am J Hum Genet 2004; 75:504.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee AT, Li W, Liew A, et al. The PTPN22 R620W polymorphism associates with RF positive rheumatoid arthritis in a dose-dependent manner but not with HLA-SE status. Genes Immun 2005; 6:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Qu H, Tessier MC, Hudson TJ, Polychronakos C. Confirmation of the association of the R620W polymorphism in the protein tyrosine phosphatase PTPN22 with type 1 diabetes in a family based study. J Med Genet 2005; 42:266.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Netea MG, Brown GD, Kullberg BJ, Gow NA. An integrated model of the recognition of Candida albicans by the innate immune system. Nat Rev Microbiol 2008; 6:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Netea MG, Gow NA, Munro CA, et al. Immune sensing of Candida albicans requires cooperative recognition of mannans and glucans by lectin and Toll-like receptors. J Clin Invest 2006; 116:1642.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jouault T, Ibata-Ombetta S, Takeuchi O, et al. Candida albicans phospholipomannan is sensed through toll-like receptors. J Infect Dis 2003; 188:165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown GD, Herre J, Williams DL, et al. Dectin-1 mediates the biological effects of beta-glucans. J Exp Med 2003; 197:1119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor PR, Tsoni SV, Willment JA, et al. Dectin-1 is required for beta-glucan recognition and control of fungal infection. Nat Immunol 2007; 8:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gantner BN, Simmons RM, Canavera SJ, et al. Collaborative induction of inflammatory responses by dectin-1 and Toll-like receptor 2. J Exp Med 2003; 197:1107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nahum A, Dadi H, Bates A, Roifman CM. The L412F variant of Toll-like receptor 3 (TLR3) is associated with cutaneous candidiasis, increased susceptibility to cytomegalovirus, and autoimmunity. J Allergy Clin Immunol 2011; 127:528.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okada S, Markle JG, Deenick EK, et al. IMMUNODEFICIENCIES. Impairment of immunity to Candida and Mycobacterium in humans with bi-allelic RORC mutations. Science 2015; 349:606.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meager A, Visvalingam K, Peterson P, et al. Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. PLoS Med 2006; 3:e289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meloni A, Furcas M, Cetani F, et al. Autoantibodies against type I interferons as an additional diagnostic criterion for autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metab 2008; 93:4389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kirkpatrick CH, Chandler JW, Schimke RN. Chronic mucocutaneous moniliasis with impaired delayed hypersensitivity. Clin Exp Immunol 1970; 6:375.
          </a>
         </li>
         <li class="breakAll">
          Nahum A, Roifman CM, et al, 2010, personal communication.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bentur L, Nisbet-Brown E, Levison H, Roifman CM. Lung disease associated with IgG subclass deficiency in chronic mucocutaneous candidiasis. J Pediatr 1991; 118:82.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalfa VC, Roberts RL, Stiehm ER. The syndrome of chronic mucocutaneous candidiasis with selective antibody deficiency. Ann Allergy Asthma Immunol 2003; 90:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ersoy F, Berkel AI, Sanal O, Oktay H. Twenty-year follow-up of 160 patients with ataxia-telangiectasia. Turk J Pediatr 1991; 33:205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roth S, Ruland J. Caspase recruitment domain-containing protein 9 signaling in innate immunity and inflammation. Trends Immunol 2013; 34:243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glocker EO, Hennigs A, Nabavi M, et al. A homozygous CARD9 mutation in a family with susceptibility to fungal infections. N Engl J Med 2009; 361:1727.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drewniak A, Gazendam RP, Tool AT, et al. Invasive fungal infection and impaired neutrophil killing in human CARD9 deficiency. Blood 2013; 121:2385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lanternier F, Pathan S, Vincent QB, et al. Deep dermatophytosis and inherited CARD9 deficiency. N Engl J Med 2013; 369:1704.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang X, Wang W, Lin Z, et al. CARD9 mutations linked to subcutaneous phaeohyphomycosis and TH17 cell deficiencies. J Allergy Clin Immunol 2014; 133:905.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lanternier F, Barbati E, Meinzer U, et al. Inherited CARD9 deficiency in 2 unrelated patients with invasive Exophiala infection. J Infect Dis 2015; 211:1241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pérez de Diego R, Sánchez-Ramón S, López-Collazo E, et al. Genetic errors of the human caspase recruitment domain-B-cell lymphoma 10-mucosa-associated lymphoid tissue lymphoma-translocation gene 1 (CBM) complex: Molecular, immunologic, and clinical heterogeneity. J Allergy Clin Immunol 2015; 136:1139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Beaucoudrey L, Puel A, Filipe-Santos O, et al. Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells. J Exp Med 2008; 205:1543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Renner R, Hipler C, Treudler R, et al. Identification of a 27 kDa protein in patients with anaphylactic reactions to mango. J Investig Allergol Clin Immunol 2008; 18:476.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Milner JD, Brenchley JM, Laurence A, et al. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 2008; 452:773.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chu EY, Freeman AF, Jing H, et al. Cutaneous manifestations of DOCK8 deficiency syndrome. Arch Dermatol 2012; 148:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ouederni M, Sanal O, Ikinciogullari A, et al. Clinical features of Candidiasis in patients with inherited interleukin 12 receptor β1 deficiency. Clin Infect Dis 2014; 58:204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prando C, Samarina A, Bustamante J, et al. Inherited IL-12p40 deficiency: genetic, immunologic, and clinical features of 49 patients from 30 kindreds. Medicine (Baltimore) 2013; 92:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fukushima C, Matsuse H, Tomari S, et al. Oral candidiasis associated with inhaled corticosteroid use: comparison of fluticasone and beclomethasone. Ann Allergy Asthma Immunol 2003; 90:646.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hachiya KA, Kobayashi RH, Antonson DL. Candida esophagitis following antibiotic usage. Pediatr Infect Dis 1982; 1:168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Husebye ES, Perheentupa J, Rautemaa R, Kämpe O. Clinical manifestations and management of patients with autoimmune polyendocrine syndrome type I. J Intern Med 2009; 265:514.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burke WA. Use of itraconazole in a patient with chronic mucocutaneous candidiasis. J Am Acad Dermatol 1989; 21:1309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kirkpatrick CH. Chronic mucocutaneous candidiasis. Pediatr Infect Dis J 2001; 20:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kamai Y, Maebashi K, Kudoh M, et al. Characterization of mechanisms of fluconazole resistance in a Candida albicans isolate from a Japanese patient with chronic mucocutaneous candidiasis. Microbiol Immunol 2004; 48:937.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rautemaa R, Richardson M, Pfaller MA, et al. Activity of amphotericin B, anidulafungin, caspofungin, micafungin, posaconazole, and voriconazole against Candida albicans with decreased susceptibility to fluconazole from APECED patients on long-term azole treatment of chronic mucocutaneous candidiasis. Diagn Microbiol Infect Dis 2008; 62:182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Füchtenbusch M, Vogel A, Achenbach P, et al. Lupus-like panniculitis in a patient with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED). Exp Clin Endocrinol Diabetes 2003; 111:288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Padeh S, Theodor R, Jonas A, Passwell JH. Severe malabsorption in autoimmune polyendocrinopathy-candidosis-ectodermal dystrophy syndrome successfully treated with immunosuppression. Arch Dis Child 1997; 76:532.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wildbaum G, Shahar E, Katz R, et al. Continuous G-CSF therapy for isolated chronic mucocutaneous candidiasis: complete clinical remission with restoration of IL-17 secretion. J Allergy Clin Immunol 2013; 132:761.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Higgins E, Al Shehri T, McAleer MA, et al. Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation. J Allergy Clin Immunol 2015; 135:551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meesilpavikkai K, Dik WA, Schrijver B, et al. Baricitinib treatment in a patient with a gain-of-function mutation in signal transducer and activator of transcription 1 (STAT1). J Allergy Clin Immunol 2018; 142:328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoh MC, Lin HP, Chan LL, Lam SK. Successful allogeneic bone marrow transplantation in severe chronic mucocutaneous candidiasis syndrome. Bone Marrow Transplant 1996; 18:797.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levy RL, Bach ML, Huang S, et al. Thymic transplantation in a case of chronic mucocutaneous candidiasis. Lancet 1971; 2:898.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kirkpatrick CH, Ottenson EA, Smith TK, et al. Reconstitution of defective cellular immunity with foetal thymus and dialysable transfer factor. Long-term studies in a patient with chronic mucocutaneous candidiasis. Clin Exp Immunol 1976; 23:414.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ballow M, Hyman LR. Combination immunotherapy in chronic mucocutaneous candidiasis. Synergism between transfer factor and fetal thymus tissue. Clin Immunol Immunopathol 1977; 8:504.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valdimarsson H, Moss PD, Holt PJ, H OBBS JR. Treatment of chronic mucocutaneous candidiasis with leucocytes from HL-A compatible sibling. Lancet 1972; 1:469.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kirkpatrick CH, Rich RR, Graw RG Jr, et al. Treatment of chronic mucocutaneous moniliasis by immunologic reconstitution. Clin Exp Immunol 1971; 9:733.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 13569 Version 31.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Chronic tetany and chronic mycelia stomatitis in a child aged four and one half years
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14375372" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Chronic moniliasis associated with Addison's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13367177" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : The syndrome of familial juvenile hypoadrenocorticism, hypoparathyroidism and superficial moniliasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14050969" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : A POSSIBLE AUTOIMMUNE BASIS FOR ADDISON'S DISEASE IN THREE SIBLINGS, ONE WITH IDIOPATHIC HYPOPARATHYROIDISM, PERNICIOUS ANEMIA AND SUPERFICIAL MONILIASIS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5663728" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Candidiasis: studies pertaining to its association with endocrinopathies and pernicious anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2308026" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Chronic mucocutaneous candidiasis in childhood and complications of non-Candida infection: a report of the Pediatric Immunodeficiency Collaborative Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7496919" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Autoimmune hemolytic anemia in chronic mucocutaneous candidiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/124324" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Chronic mucocutaneous candidiasis with macrophage dysfunction, a plasma inhibitor, and co-existent aplastic anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3518164" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Severe aplastic anemia associated with chronic mucocutaneous candidiasis. Immunologic and hematologic reconstitution after allogeneic bone marrow transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/377963" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Mucocutaneous candidiasis and thymoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2348835" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9398840" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16459069" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : The why and how of thymocyte negative selection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10208866" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Autoimmune regulator is expressed in the cells regulating immune tolerance in thymus medulla.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16551260" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : A central role for central tolerance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12376594" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Projection of an immunological self shadow within the thymus by the aire protein.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16111640" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : The cellular mechanism of Aire control of T cell tolerance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12612579" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Aire regulates negative selection of organ-specific T cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11803052" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Expression of AIRE gene in peripheral monocyte/dendritic cell lineage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17195844" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Peripheral antigen display by lymph node stroma promotes T cell tolerance to intestinal self.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9543115" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Clinical review 93: Autoimmune polyglandular syndrome type 1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11023146" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12050215" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : AIRE mutations and human leukocyte antigen genotypes as determinants of the autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy phenotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12050123" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9920103" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : DRB1*04 and DQ alleles: expression of 21-hydroxylase autoantibodies and risk of progression to Addison's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18755889" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : B cells are required for Aire-deficient mice to develop multi-organ autoinflammation: A therapeutic approach for APECED patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21901851" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Autoimmune polyendocrine syndrome type 1: Utility of KCNRG autoantibodies as a marker of active pulmonary disease and successful treatment with rituximab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25273396" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Induction of thyroid remission using rituximab in a patient with type 3 autoimmune polyglandular syndrome including Graves' disease and type 1 diabetes mellitus: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24711434" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Kidney involvement in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy in a Finnish cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27142200" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Autoimmune polyglandular syndrome type I can have significant kidney disease in children including recurrence in renal allograft - a report of two cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20123958" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20123959" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21109174" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Anticytokine autoantibodies in infectious diseases: pathogenesis and mechanisms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24493573" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Autoantibodies to IL-17A may be correlated with the severity of mucocutaneous candidiasis in APECED patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20934207" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Impaired T(H)17 responses in patients with chronic mucocutaneous candidiasis with and without autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21962774" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Autoimmune regulator (AIRE) contributes to Dectin-1-induced TNF-αproduction and complexes with caspase recruitment domain-containing protein 9 (CARD9), spleen tyrosine kinase (Syk), and Dectin-1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16684821" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23723078" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy from the pediatric perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21295522" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Clinical heterogeneity and diagnostic delay of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1130807" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Candidiasis and multiple endocrinopathy. With oral squamous cell carcinoma complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17852718" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Chronic mucocutaneous candidiasis and oesophageal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11037909" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Chronic bilateral keratitis in autoimmune polyendocrinopathy-candidiadis-ectodermal dystrophy (APECED). A long-term follow-up and visual prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10084559" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Severe autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy in an adolescent girl with a novel AIRE mutation: response to immunosuppressive therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16263818" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome with renal failure: impact of posttransplant immunosuppression on disease activity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21197407" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Renal failure associated with APECED and terminal 4q deletion: evidence of autoimmune nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27588307" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Redefined clinical features and diagnostic criteria in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22520844" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : The JAK-STAT pathway at twenty.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21714643" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22730530" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Chronic mucocutaneous candidiasis caused by a gain-of-function mutation in the STAT1 DNA-binding domain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23541320" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations and disseminated coccidioidomycosis and histoplasmosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23534974" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Dominant gain-of-function STAT1 mutations in FOXP3 wild-type immune dysregulation-polyendocrinopathy-enteropathy-X-linked-like syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21727188" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23040277" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Molecular mechanisms of mucocutaneous immunity against Candida and Staphylococcus species.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28258222" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Molecular mechanism and structural basis of gain-of-function of STAT1 caused by pathogenic R274Q mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28348565" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : A Novel Heterozygous Mutation in the STAT1 SH2 Domain Causes Chronic Mucocutaneous Candidiasis, Atypically Diverse Infections, Autoimmunity, and Impaired Cytokine Regulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24239102" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Fatal combined immunodeficiency associated with heterozygous mutation in STAT1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Clinical manifestations associated with novel mutations in the coiled-coil domain of STAT1
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28069426" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Impaired natural killer cell functions in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Monoallelic STAT1 mutations and disease patterns
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26604104" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : The Extended Clinical Phenotype of 26 Patients with Chronic Mucocutaneous Candidiasis due to Gain-of-Function Mutations in STAT1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26732859" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Clinical heterogeneity of dominant chronic mucocutaneous candidiasis disease: presenting as treatment-resistant candidiasis and chronic lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24709374" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation-related primary immunodeficiency is associated with disseminated mucormycosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : A mutation in the STAT1 DNA-binding domain associated with hemophagocytic lymphohistocytosis
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9787702" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Cerebral vasculitis associated with chronic mucocutaneous candidiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21350122" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27930337" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Genetic, immunological, and clinical features of patients with bacterial and fungal infections due to inherited IL-17RA deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28090315" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Chronic mucocutaneous candidiasis disease associated with inborn errors of IL-17 immunity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25918342" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Inherited IL-17RC deficiency in patients with chronic mucocutaneous candidiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24120361" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : An ACT1 mutation selectively abolishes interleukin-17 responses in humans with chronic mucocutaneous candidiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19084113" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Association of the lymphoid protein tyrosine phosphatase, R620W variant, with chronic mucocutaneous candidiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19864674" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Human dectin-1 deficiency and mucocutaneous fungal infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10068674" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Cloning and characterization of a lymphoid-specific, inducible human protein tyrosine phosphatase, Lyp.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16461343" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Identification of substrates of human protein-tyrosine phosphatase PTPN22.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10601992" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Characterization of TCR-induced receptor-proximal signaling events negatively regulated by the protein tyrosine phosphatase PEP.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16273109" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9582365" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Sequence requirements for association of protein-tyrosine phosphatase PEP with the Src homology 3 domain of inhibitory tyrosine protein kinase p50(csk).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15004560" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16697661" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Role of PTPN22 in type 1 diabetes and other autoimmune diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15719322" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Analysis of families in the multiple autoimmune disease genetics consortium (MADGC) collection: the PTPN22 620W allele associates with multiple autoimmune phenotypes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17170052" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Investigation of genetic variation across the protein tyrosine phosphatase gene in patients with rheumatoid arthritis in the UK.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16868974" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Evaluation of the genetic association of the PTPN22 R620W polymorphism in familial and sporadic systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15273934" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15674368" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : The PTPN22 R620W polymorphism associates with RF positive rheumatoid arthritis in a dose-dependent manner but not with HLA-SE status.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15744042" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Confirmation of the association of the R620W polymorphism in the protein tyrosine phosphatase PTPN22 with type 1 diabetes in a family based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18079743" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : An integrated model of the recognition of Candida albicans by the innate immune system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16710478" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Immune sensing of Candida albicans requires cooperative recognition of mannans and glucans by lectin and Toll-like receptors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12825186" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Candida albicans phospholipomannan is sensed through toll-like receptors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12719478" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Dectin-1 mediates the biological effects of beta-glucans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17159984" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Dectin-1 is required for beta-glucan recognition and control of fungal infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12719479" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Collaborative induction of inflammatory responses by dectin-1 and Toll-like receptor 2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21093032" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : The L412F variant of Toll-like receptor 3 (TLR3) is associated with cutaneous candidiasis, increased susceptibility to cytomegalovirus, and autoimmunity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26160376" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : IMMUNODEFICIENCIES. Impairment of immunity to Candida and Mycobacterium in humans with bi-allelic RORC mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16784312" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18728167" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Autoantibodies against type I interferons as an additional diagnostic criterion for autoimmune polyendocrine syndrome type I.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5442521" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Chronic mucocutaneous moniliasis with impaired delayed hypersensitivity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5442521" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Chronic mucocutaneous moniliasis with impaired delayed hypersensitivity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1986107" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Lung disease associated with IgG subclass deficiency in chronic mucocutaneous candidiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12602677" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : The syndrome of chronic mucocutaneous candidiasis with selective antibody deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1814037" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Twenty-year follow-up of 160 patients with ataxia-telangiectasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23523010" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Caspase recruitment domain-containing protein 9 signaling in innate immunity and inflammation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19864672" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : A homozygous CARD9 mutation in a family with susceptibility to fungal infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23335372" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Invasive fungal infection and impaired neutrophil killing in human CARD9 deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24131138" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Deep dermatophytosis and inherited CARD9 deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24231284" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : CARD9 mutations linked to subcutaneous phaeohyphomycosis and TH17 cell deficiencies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25057046" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Inherited CARD9 deficiency in 2 unrelated patients with invasive Exophiala infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26277595" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Genetic errors of the human caspase recruitment domain-B-cell lymphoma 10-mucosa-associated lymphoid tissue lymphoma-translocation gene 1 (CBM) complex: Molecular, immunologic, and clinical heterogeneity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18591412" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19123442" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Identification of a 27 kDa protein in patients with anaphylactic reactions to mango.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18337720" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21931011" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Cutaneous manifestations of DOCK8 deficiency syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24186907" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Clinical features of Candidiasis in patients with inherited interleukin 12 receptorβ1 deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23429356" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Inherited IL-12p40 deficiency: genetic, immunologic, and clinical features of 49 patients from 30 kindreds.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12839324" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Oral candidiasis associated with inhaled corticosteroid use: comparison of fluticasone and beclomethasone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7145730" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Candida esophagitis following antibiotic usage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19382991" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Clinical manifestations and management of patients with autoimmune polyendocrine syndrome type I.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2555403" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Use of itraconazole in a patient with chronic mucocutaneous candidiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11224843" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Chronic mucocutaneous candidiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15611610" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Characterization of mechanisms of fluconazole resistance in a Candida albicans isolate from a Japanese patient with chronic mucocutaneous candidiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18597968" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Activity of amphotericin B, anidulafungin, caspofungin, micafungin, posaconazole, and voriconazole against Candida albicans with decreased susceptibility to fluconazole from APECED patients on long-term azole treatment of chronic mucocutaneous candidiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12951636" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Lupus-like panniculitis in a patient with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9245854" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Severe malabsorption in autoimmune polyendocrinopathy-candidosis-ectodermal dystrophy syndrome successfully treated with immunosuppression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23791509" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Continuous G-CSF therapy for isolated chronic mucocutaneous candidiasis: complete clinical remission with restoration of IL-17 secretion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25662309" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29729898" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Baricitinib treatment in a patient with a gain-of-function mutation in signal transducer and activator of transcription 1 (STAT1).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8899198" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Successful allogeneic bone marrow transplantation in severe chronic mucocutaneous candidiasis syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4106659" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Thymic transplantation in a case of chronic mucocutaneous candidiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/947642" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Reconstitution of defective cellular immunity with foetal thymus and dialysable transfer factor. Long-term studies in a patient with chronic mucocutaneous candidiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/912947" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Combination immunotherapy in chronic mucocutaneous candidiasis. Synergism between transfer factor and fetal thymus tissue.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4109818" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Treatment of chronic mucocutaneous candidiasis with leucocytes from HL-A compatible sibling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4945734" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Treatment of chronic mucocutaneous moniliasis by immunologic reconstitution.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
